Attached files
| file | filename |
|---|---|
| EX-21 - EX-21 - NOVELION THERAPEUTICS INC. | d70832dex21.htm |
| EX-23 - EX-23 - NOVELION THERAPEUTICS INC. | d70832dex23.htm |
| EX-31.1 - EX-31.1 - NOVELION THERAPEUTICS INC. | d70832dex311.htm |
| EX-32.1 - EX-32.1 - NOVELION THERAPEUTICS INC. | d70832dex321.htm |
| EX-32.2 - EX-32.2 - NOVELION THERAPEUTICS INC. | d70832dex322.htm |
| EX-31.2 - EX-31.2 - NOVELION THERAPEUTICS INC. | d70832dex312.htm |
| EX-10.28 - EX-10.28 - NOVELION THERAPEUTICS INC. | d70832dex1028.htm |
| EX-10.27 - EX-10.27 - NOVELION THERAPEUTICS INC. | d70832dex1027.htm |
| XML - IDEA: XBRL DOCUMENT - NOVELION THERAPEUTICS INC. | R9999.htm |
| 10-K - 10-K - NOVELION THERAPEUTICS INC. | d70832d10k.htm |
| EX-10.29 - EX-10.29 - NOVELION THERAPEUTICS INC. | d70832dex1029.htm |
EXHIBIT 11
COMPUTATION OF PER SHARE EARNINGS
Basic net income per common share is computed using the weighted average number of common shares outstanding during the period. Diluted net income per common share is computed in accordance with the treasury stock method and the “if converted” method, which uses the weighted average number of common shares outstanding during the period and also includes the dilutive effect of potentially issuable common stock from outstanding stock options and restricted stock units. Common shares issuable upon exercise of certain options are not used in the calculation for the years ended December 31, 2011 to 2015, as the effect would be anti-dilutive.
| Year ended December 31, | ||||||||||||||||||||
| 2015 | 2014 | 2013 | 2012 | 2011 | ||||||||||||||||
| (In thousands of U.S. dollars except per share information) | ||||||||||||||||||||
|
Loss from continuing operations |
$ | (23,009 | ) | $ | (4,005 | ) | $ | (25,838 | ) | $ | (42,264 | ) | $ | (31,379 | ) | |||||
| (Loss) income from discontinued operations, net of income tax | — | (66 | ) | 967 | 87,962 | 963 | ||||||||||||||
| Net (loss) income available to common shareholders | $ | (23,009 | ) | $ | (4,071 | ) | $ | (24,871 | ) | $ | 45,698 | $ | (30,416 | ) | ||||||
| Basic net (loss) income per common share | ||||||||||||||||||||
| Continuing operations |
(0.44 | ) | (0.08 | ) | (0.51 | ) | (0.84 | ) | (0.63 | ) | ||||||||||
| Discontinued operations |
— | (0.00 | ) | 0.02 | 1.75 | 0.02 | ||||||||||||||
|
Net (loss) income per common share |
$ | (0.44 | ) | $ | (0.08 | ) | $ | (0.49 | ) | $ | 0.91 | $ | (0.61 | ) | ||||||
|
Diluted net (loss) income per common share |
||||||||||||||||||||
| Continuing operations |
(0.44 | ) | (0.08 | ) | (0.51 | ) | (0.84 | ) | (0.63 | ) | ||||||||||
| Discontinued operations |
— | (0.00 | ) | 0.02 | 1.75 | 0.02 | ||||||||||||||
|
Net (loss) income per common share |
$ | (0.44 | ) | $ | (0.08 | ) | $ | (0.49 | ) | $ | 0.91 | $ | (0.61 | ) | ||||||
|
Weighted average number of common shares outstanding (in thousands) |
52,169 | 51,126 | 50,909 | 50,112 | 50,105 | |||||||||||||||
| Diluted weighted average number of common shares outstanding (in thousands) | 52,169 | 51,126 | 50,909 | 50,112 | 50,105 | |||||||||||||||